Neos Therapeutics, which is developing easily swallowed formulations of ADHD treatments, raised $72 million by offering 4.8 million shares (upsized from 4.0 million) at $15, the midpoint of the range of $14 to $16. Neos Therapeutics plans to list on the Nasdaq under the symbol NEOS. Neos Therapeutics initially filed confidentially on 4/27/2015. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets acted as lead managers on the deal.
